Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture

June 25, 2020

Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for the sterile manufacture of AZD1222, a COVID-19 recombinant adenovirus vaccine, to be used in clinical trials.

Symbiosis Pharmaceutical Services has signed a supply agreement with AstraZeneca for the sterile manufacture of AZD1222, a COVID-19 recombinant adenovirus vaccine, to be used in clinical trials.

According to a June 22, 2020 press release, the terms of the agreement will see Symbiosis provide AstraZeneca with fast-track access to sterile vaccine drug product manufacturing capacity. This latest news follows from AstraZeneca’s licensing agreement with the University of Oxford for the global development, manufacture, and distribution of AZD1222 vaccine candidate, which is currently in clinical trials at multiple sites in the United Kingdom.

“Our team is immensely proud to be able to make a highly meaningful contribution to the global fight against COVID-19 and the urgent efforts to develop a successful vaccine,” said Colin MacKay, founder and CEO of Symbiosis, in the press release. “With many years of direct experience manufacturing medicines and vaccines of this nature for clinical trials and commercial markets, we are delighted to be able to leverage our expertise and competitive strengths to accelerate the development of this vaccine for AstraZeneca and to add value to the project.”

Symbiosis Pharmaceutical Services is a specialist provider of pharmaceutical and vaccine development services in Stirling, Scotland.

Source: Symbiosis